1)日本核医学会PET核医学委員会,日本アイソトープ協会医学・薬学部会.PET検査件数に関するアンケート調査報告─第10報.Isotope news 712:38-42, 2013
2)Vitra JV, Delbeke D, Sandler MP, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 171:21-26, 1996
3)Thoeni RF. Colorectal cancer. Radiologic staging. Radiol Clin North Am 35:457-485, 1997
4)加藤貴司,中川学,中川宗一,他.全身18F-FDG-PET検査による大腸腫瘍の検出能の検討.日大腸検会誌 19:88-91, 2002
5)Yasuda S, Fujii H, Nakahara T, et al. 18F-FDG PET detection of colonic adenomas. J Nucl Med 42:989-992, 2001
6)Arslan N, Dehdashti F, Siegel BA. FDG uptake in colonic villous adenomas. Ann Nucl Med 19:331-334, 2005
7)Whiteford MH, Whiteford HM, Yee LF, et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 43:759-767, 2000
8)Domeki Y, Murakami K, Kato H, et al. Effects of a proton pump inhibitor on the physiological accumulation of fluoro-2-deoxy-D-glucose(FDG)in HDG-positron emission tomography. Surg Today 42:927-933, 2012
9)日本医学放射線学会,日本放射線科専門医会・医会(編).画像診断ガイドライン,2013年版.金原出版, 2013
10)Bamba Y, Itabashi M, Kameoka S. Clinical use of PET/CT in peritoneal carcinomatosis from colorectal cancer. Hepatogastroenterology 59:1408-1411, 2012
11)Lu YY, Chen JH, Chien CR, et al. Use of FDG-PET or PET/CT to detect recurrent colorectal cancer in patients with elevated CEA:a systematic review and meta-analysis. Int J Colorectal Dis 28:1039-1047, 2013
12)Yasuda S, Shohtsu A. Cancer screening with whole-body 18F-fluorodeoxyglucose positron-emission tomography. Lancet 350:1819, 1997
13)Minamimoto R, Senda M, Jinnouchi S, et al. The current status of an FDG-PET cancer screening program in Japan, based on a 4-year(2006-2009)nationwide survey. Ann Nucl Med 2:46-57, 2013
14)陣之内正史,立野利衣,中條正豊,他.PET検診にて発見された大腸癌の分析─便潜血検査およびCEAとの比較.日がん検診断会誌 14:150-155, 2007
15)Minamimoto R, Senda M, Jinnouchi S, et al. Detection of colorectal cancer and adenomas by FDG-PET cancer screening program:results based on a nationwide Japanese survey. Ann Nucl Med 28:212-219, 2014
16)Miettinen M, Lasota J. Gastrointestinal stromal tumors:pathology and prognosis at different sites. Semin Diagn Pathol 23:70-83, 2006
17)Kamiyama Y, Aihara R, Nakabayashi T, et al. 18F-fluorodeoxyglucose positron emission tomography:useful technique for predicting malignant potential of gastrointestinal stromal tumors. World J Surg 29:1429-1435, 2005
18)Park JW, Cho CH, Jeong DS, et al. Role of 18F-fluoro-2-deoxyglucose positron emission tomography in gastric GIST:predicting malignant potential pre-operatively. J Gastric Cancer 11:173-179, 2011
19)日本癌治療学会,日本胃癌学会,GIST研究会(編).GIST診療ガイドライン,改訂第3版.金原出版,2014
20)Demetri GD, Benjamin R, Blanke CD, et al. NCCN task force report:optimal management of patients with gastrointestinal stromal tumor(GIST)-expansion and update of NCCN clinical practice guideline. J Natl Compr Canc Netw 2(Suppl 1):S1-26, 2004
21)Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 16:566-578, 2005
22)Liu FY, Yen TC, Wang JY, et al. Early prediction by 18F-FDG PET/CT for progression-free survival and overall survival in patients with metastatic colorectal cancer receiving third-line cetuximab-based therapy. Clin Nucl Med 40:200-205, 2015
23)Iwamoto M, Kawada K, Nakamoto Y, et al. Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS. J Nucl Med 55:2038-2044, 2014
24)Binderup T, Knigge U, Loft A, et al. Functional imaging of neuroendocrine tumors:a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med 51:704-712, 2010